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The interplay between triggers, arrhythmogenic substrate and modulators determines the pathophysiological and cli-
QLFDO FRXUVH RI DWULDO ¿EULOODWLRQ&DWKHWHU DEODWLRQ LV FXUUHQWO\ WKHPDLQVWD\ RI WKHUDS\ RI WKLV FRPSOH[ DUUK\WKPLD
Although mainly based on pulmonary vein isolation empirical ablation approaches targeting extrapulmonary substrate 
have also been introduced. These include creation of linear lesions, extensive ablation of LA posterior wall, targeting 
fractionated electrograms, rotors maintaining AF, etc. However, many of these approaches are just empirical and do 
QRWSURYLGHDQLQGLYLGXDOLVHGDSSURDFKWRHDFKSDWLHQW5HFHQWO\WKHFRQFHSWRI¿EURWLFDWULDOFDUGLRP\RSDWK\KDVEHHQ
introduced to explain the occurrence and clinical course of many conditions including AF. Atrial voltage mapping is inc-
UHDVLQJO\UHFRJQLVHGDVDPHDQVWRLGHQWLI\WKRVH¿EURWLFDUHDV7DUJHWLQJORZYROWDJH]RQHVLQWKHDWULDGXULQJFDWKHWHU
ablation of AF seems to be associated with better clinical outcomes. This review focuses on the association between 
ORZYROWDJH]RQHVDQGDWULDO¿EURVLV,WFRYHUVPDQ\RIWKHWHFKQLFDOGHWDLOVDQGOLPLWDWLRQVRIYROWDJHPDSSLQJWRLGHQWLI\
atrial substrate. It also summarises the available data from clinical trials examining the role of voltage-driven ablation 
on procedural outcome on AF patients.
Introduction
From the pathophysiological standpoint atrial fibrilla-
tion (AF) is a complex disease bringing together three 
major mechanisms for its initiation and maintenance. 
These are the triggers, the arrhythmogenic substrate 
and multiple modulators. When trigger activity is the 
single or predominant mechanism of AF occurrence in 
the absence of a significant arrhythmogenic substrate 
then the AF might be considered a self-perpetuating 
process, as stated by the “AF begets AF” concept by 
Wijffels et al. (1). However, in most of the cases there 
is interplay between triggers and arrhythmogenic sub-
strate. In these cases, pre-existing fibrotic changes in 
the atria might be responsible for creating conditions 
for the triggering activity to initiate AF episodes. Such a 
scenario might even question the existence of lone AF 
as defined by lack of structural heart disease in young 
patients (2).
Currently catheter ablation is the mainstay treatment 
modality in atrial fibrillation (AF) (3, 4). Since its intro-
duction at the end of the 90-s by +DLVVDJXHUUHHWDO 
pulmonary vein isolation (PVI) has turned into the cor-
nerstone of this treatment modality (5). It is the main 
and frequently the only step undertaken during abla-
tion of paroxysmal and persistent AF. Results from PVI 
as a stand-alone procedure in patients with paroxysmal 
AF are quite promising in achieving long-term freedom 
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from arrhythmias in up to 94% especially after the in-
troduction of recent technological advancements and 
new ablation algorithms (6). Long-term success rates of 
PVI in non-paroxysmal AF (NPAF) are lower according 
to large randomised trials (7). In NPAF additional abla-
tion approaches have been proposed. These include 
stepwise ablation, defragmentation by targeting com-
plex fractionated electrograms, linear ablation, rotor 
modulation and even combined catheter ablation with 
alcohol ablation (8–11). All these techniques have been 
proven to be effective in small or single centre studies 
but never showed superiority in large randomised con-
trolled trials (7). One potential explanation for this could 
be that most of them are empirically applied to individu-
al patients all of whom might have different substrates.
Recently the term atrial cardiomyopathy was introduced 
to describe a specific entity defined as: ‘any complex 
of structural, architectural, contractile or electrophysi-
ological changes affecting the atria with the potential to 
produce clinically-relevant manifestations’ (12). These 
are a result of many pathological conditions but share 
many morphological similarities. The presence of such 
fibrotic atrial cardiomyopathy could explain a myriad of 
different clinical conditions – from AF and atrial tachy-
cardia to sinus node disease and even thromboembolic 
complications (13).
Identifying and targeting fibrotic areas during ablation 
seems to be a promising approach to tailoring ablation 
therapy to fit the specific substrate in each individual 
patient. The current review will discuss some issues on 
the association of atrial fibrosis with clinical type of AF, 
then summarise the available evidence on the associa-
tion of left atrial fibrosis on the outcome of AF ablation. 
Further on it will focus on the methods to identify fibrotic 
areas based on atrial voltage mapping covering most of 
its technical aspects. Finally, the review will summarise 
the existing data from clinical trials examining the role 
of voltage-guided ablation on procedural outcome on 
AF patients.
AF phenotype and potential pitfalls of 
non-tailored approach to AF ablation
The landmark concept of “AF begets AF” postulates 
that AF episodes would change electrical properties 
of atrial myocardium thus facilitating further AF occur-
rence (1). In an animal model the authors showed that 
bursts of high rate atrial pacing are able induce and 
maintain AF episodes of progressively longer duration. 
This was accompanied by marked changes in electro-
physiological properties of the atrial myocardium. Such 
findings might serve to explain the generally accepted 
principle that AF occurs initially as a paroxysmal ar-
rhythmia and over time it progresses into persistent AF 
of different duration (3). Many studies in humans have 
also supported these findings. However, this “natural 
evolution” of AF is not always so straightforward and 
there are series describing patients with AF initially pre-
senting as persistent cases and never going through 
the “paroxysmal phase”. On the other hand, many par-
oxysmal AF cases never progress to persistent AF de-
spite the presence of very frequent episodes. Actually 
several groups have investigated the characteristics 
of patients with persistent AF “early in the course” or 
“directly from the onset” demonstrating characteristics 
suggesting more expressed arrhythmogenic substrate 
and poor outcome of the ablation (14, 15). There is also 
data showing very advanced atrial fibrosis in patients 
with paroxysmal AF and only mild fibrotic changes in 
persistent AF patients as assessed by histological stu d ies 
and markers of collagen synthesis (16). Mahnkopf et al. 
demonstrated that the extent of LA fibrosis as assessed 
by late enhancement on magnetic resonance imaging 
(DE-MRI) is not dependent on AF type and the pres-
ence of comorbidities (2). In another series Stiles et al. 
report structural and electrophysiological abnormalities 
even in patients with “lone” paroxysmal AF (17). These 
findings question the concept that AF burden or persis-
tence play a significant role in the development of atrial 
fibrosis. Therefore, from the standpoint of the degree 
of arrhythmogenic substrate the mechanistic division of 
AF into paroxysmal and persistent forms seems to be 
inappropriate.
Selecting patients who would require substrate modifi-
cation as an additive to PVI based only on clinical pres-
entation might not be entirely justified. Applying more 
extensive empirical ablation without identifying the un-
derlying arrhythmogenic substrate may lead to over-
treatment with subsequent increase in procedure dura-
tion, X-ray exposure and increased complication rate. 
Furthermore, some patients would remain undertreated 
and show more arrhythmia recurrences.
Atrial voltage as a marker of atrial fibrosis
The term arrhythmogenic substrate has been used to 
represent all the structural changes in the atrial myo-
cardium which predispose to AF – LA fibrosis, atrial 
dysfunction, ultrastructural changes, etc. Obviously, im-
aging would represent the modality of choice to identify 
atrial fibrosis. Of the available imaging modalities mag-
netic resonance imaging (MRI) has been put forward as 
a means to assess LA fibrosis. Several studies demon-
strate the value of delayed enhancement MRI (DE-MRI) 
to delineate the areas of LA fibrosis. However, this im-
aging modality is not completely standardized, and it 
comes with many pitfalls and unresolved issues. It usu-
ally requires considerable postprocessing using dedi-
cated software (2). Atrial fibrosis assessed by histologi-
cal examination has been found to correlate with zones 
of DE-MRI as shown by McGann et al. (18). Numer-
ous studies using DE-MRI have demonstrated different 
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outcomes of AF ablation based on extent of delayed 
enhancement on MRI (2, 18, 19). Based on the extent 
of LA fibrosis expressed as a percentage of zones of 
DE-MRI compared to the area of the whole LA the Utah 
classification (Utah I to IV) have been introduced.
Whether atrial bipolar voltage correlates with the areas 
of late enhancement has been studied by many groups. 
Spragg et al. have demonstrated that areas of DE-MRI 
showed lower voltage as compared to areas with normal 
MRI characteristics (20). They studied 10 patients un-
dergoing redo AF ablation. Electroanatomical LA maps 
were created for each patient and co-registered with 
a preacquired MRI scan. The mean voltage of points 
identified as scar by MRI was lower than the voltage 
of points taken from non-scar regions (0.39 ± 0.6 1mV 
vs. 1.38 ± 1.23 mV, P< 0.01). DE-MRI in this study was 
found to identify areas of low voltage (0.5 mV) with a 
sensitivity of 84% and specificity of 68%. Another study 
investigates the atrial voltage in 21 patients with paro-
xysmal AF by creating a high-density electro-anatomi-
cal map of the LA (21). The acquired voltage maps were 
registered together with the preacquired MRI models. 
Their results show that increasing levels of late gadolin-
ium enhancement were associated with progressively 
lower endocardial voltage. Not all studies, however, re-
port such a straightforward relationship. For instance, 
a study by Jadidi et al. examined 18 patients with per-
sistent AF in an attempt to correlate the areas of LA 
fibrosis as assessed by MRI to zones of fractionated 
EGMs. They found that the mean voltage in the zones 
of dense late gadolinium enhancement was only slight-
ly, but significantly lower than the ones recorded in the 
non-fibrotic regions (0.6 ± 0.8 mV vs. 0.86 ± 0.89 mV, 
P<0.001). .KXUUDPHWDO have studied 75 patients with 
AF in order to clarify the correlation between abnormal 
voltage and the presence and distribution of LA fibrosis 
(22). They have designed a specific MRI parameter – 
the regional image intensity ratio (IIR) which represents 
the ratio between the mean pixel intensity for each sec-
tor (overall the LA area was divided into 20 sectors) di-
vided by the mean pixel intensity of the whole LA blood 
pool. All the patients underwent detailed high-density 
endocardial LA voltage map during sinus rhythm before 
ablation. The results from this study show that IIR cor-
relates strongly with bipolar LA voltage so that local IIR 
thresholds of >0.97 and >1.61 corresponded to atrial bi-
polar voltage <0.5 and <0.1 mV, respectively. Following 
adjustment for some clinical characteristics and other 
covariates the authors report that each unit increase in 
local IIR was associated with a significant 91.3% reduc-
tion in local bipolar atrial voltage.
Several other factors have been shown to have an im-
pact on the atrial voltage. Among these is LA size which 
was found to be associated with lower mean atrial volt-
age (23). A possible explanation for this is the poten-
tial link between atrial wall stress and morphological 
changes. A similar correlation has also been found 
between atrial pressure and mean atrial voltage (24). 
Many echocardiographic parameters of atrial function 
such as LA emptying fraction, total LA strain have also 
been shown to correlate with atrial voltage demonstrat-
ing the potential of these parameters to serve as indi-
rect evidence for the presence of atrial fibrosis (25, 26).
Defining atrial substrate by  
electro-anatomical voltage mapping
Defining a universal threshold for the presence of atrial 
fibrosis in AF patients would represent a major break-
through to the understanding and better identification of 
the arrhythmogenic substrate. Many centres accept the 
value of 0.5 mV as an atrial voltage threshold to identify 
abnormal areas affected by atrial fibrosis although this 
finding lacks proper pathological validation. Available 
data is quite heterogeneous and demonstrates lack of 
a widely accepted voltage threshold that could serve to 
demonstrate abnormality. Most of the studies use the 
5th centile of the voltage at all the mapping points to de-
fine abnormalities.
Some studies have examined patients with supraven-
tricular tachycardia undergoing LA mapping in an at-
tempt to identify “normal” LA voltage in “healthy” pa-
tients and compare them to AF patients. The study 
by Yagishita et al. studied 6 patients with apparently 
“healthy” atria and demonstrated that 95% of the bipo-
lar electrograms had bipolar voltage of >1.17 mV (27). In 
an elegant study Saghy et al. examined the association 
of fractionated electrograms in AF and in sinus rhythm 
in patients with persistent AF (28). This study included 
a control group of 9 patients with structurally normal 
hearts and non-AF substrates (WPW or supraventricu-
lar tachycardia). The authors found that in the control 
group 95% of all bipolar electrograms were >0.5 mV. 
On the other hand, 7HKHWDO demonstrate in a group of 
15 patients with supraventricular tachycardia that mean 
LA voltage decreases progressively among patients 
without structural heart disease and with supraven-
tricular tachycardia (2.8 mV), paroxysmal AF (2.2 mV) 
and persistent AF (1.8 mV) (29). All these findings sup-
port the notion of a lack of a clear cut-off value for LA 
voltage to identify atrial substrate. To some extent the 
discrepant results, both in non-AF and in AF patients 
might be explained by different approach for mapping.
Other studies attempt to determine the cut-off values 
for “normal” AF voltage in AF patients and use this 
value to analyse outcomes and other procedural and 
clinical endpoints. In a large series of 700 patients un-
dergoing pulmonary vein isolation Verma et al. per-
formed LA electroanatomical map searching for areas 
of LA scarring (30). In this study scar was defined as 
signal amplitude <0.05 mV and amplitudes <0.5 mV 
were used to define “abnormal” areas. Based on these 
definitions presence of LA scarring was found to be 
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an independent predictor of arrhythmia recurrence fol-
lowing catheter ablation. In another series Kapa et al. 
studied 20 patients with AF (31). According to their re-
sults a voltage cut-off of <0.2 mV at the junction of LA 
and PVs and <0.45 mV at all other areas was useful 
to identify scar at these locations. In addition, a cut-off 
value of 0.27 mV had the highest diagnostic accuracy 
to delineate scar as identified by MRI. A study by Rolf 
et al. also reports values higher than 0.5 mv to repre-
sent “healthy” areas while values in the range 0.2 to 0.5 
mV were considered diseased areas and voltage <0.2 
mV was thought to represent atrial scar (32). Contrary 
to that, the work of Kottkamp et al. suggests different 
range of values with voltages <0.5 mV thought to rep-
resent areas of severe fibrosis, those between 0.5 and 
1.5 mV – zones of mild/moderate fibrosis and >1.5 mV 
would signify “less affected/normal” myocardium. In ad-
dition, scar was defined only at sites where there was 
evident lack of discreet electrical activity and inability to 
achieve local capture during pacing. As shown above 
this group introduced the term fibrotic atrial cardiomyo-
pathy and established a classification based on the ex-
tent of abnormal areas: FACM 0 to 4 similar to the Utah 
classification (13, 33). An explanation for the apparently 
“liberal” definition of low voltage zones comes from the 
fact that this group has identified abnormal fragmented 
electrograms (also a marker of fibrosis) in the voltage 
range of even 1.5-2.5 mV. A similar approach has also 
been put forward by other groups. Yang et al. have ex-
amined 86 consecutive patients with non-paroxysmal 
AF (NPAF) in whom they performed high-density LA 
mapping in sinus rhythm, following ablation and cardio-
version. They used similar definitions of low atrial volt-
age: 0.1 to 0.4 mV were used to define low-voltage zone 
and bipolar voltage range of 0.4 to 1.3 mV was chosen 
to represent transitional zones (34).
Technical aspects of voltage mapping: role 
of underlying rhythm
The underlying rhythm during mapping appears to be an 
important factor determining atrial voltage. In an early 
study Ndrepepa et al. demonstrate that bipolar signals 
during AF demonstrate significantly lower amplitudes in 
both atria as compared to sinus rhythm (35). 7HKHWDO 
studied 12 patients with persistent AF undergoing abla-
tion. All the patients had high-density electroanatomi-
cal maps collected during AF and atrial pacing from the 
coronary sinus following AF conversion. The authors 
demonstrate that mean atrial voltages were signifi-
cantly lower during AF (0.7 ± 0.2 mV vs. 2.1 ± 0.6 mV, 
P <0.001). Another series of 9 AF patients undergoing 
high-density LA mapping during AF, sinus rhythm and 
coronary sinus pacing has been reported by Jadidi et 
al. (36). Their data shows that mean LA voltage during 
is dependent on the type of arrhythmia with paroxys-
mal AF patients showing significantly higher LA volt-
ages (1.12 ± 1.32 mV) compared to persistent AF cases 
(0.6 ± 0.59 mV), P<0.01. On the other hand, voltages 
at all mapping sites recorded during orga nised atrial 
rhythm (sinus or coronary sinus pacing) were >1 mV 
with mean LA voltage being significantly higher than 
the ones recorded during paroxysmal or persistent AF. 
Zones of low amplitudes in AF demonstrated normal 
EGM amplitude in sinus rhythm. In addition, there was 
no correlation between electrogram fractionation and 
LA voltage during organised atrial rhythm suggesting 
the purely functional nature of low voltage and EGM 
fractionation in AF patients. Similar results have been 
reported by 0DVXGD HW DO in a group of 30 patients 
with persistent AF (37). According to their data elec-
trogram amplitudes during sinus rhythm were higher 
than those during AF (1.77 ± 1.27 mV vs. 0.96 ± 0.77 
mV, P<0.0001). For each specific site electrogram am-
plitude during AF correlated only weakly with the am-
plitudes in sinus rhythm. The authors concluded that 
in patients with persistent AF there are significant dis-
parities between electrogram amplitudes during sinus 
rhythm and AF at the same locations. Electrogram am-
plitudes recorded during organised atrial rhythm might 
also be variable depending on rate and direction of 
activation of the atrial myocardium. In a recent study, 
Wong et al. examine atrial substrate characteristics 
during pacing from the left superior pulmonary vein and 
from the coronary sinus at two different cycle lengths 
in 73 AF patients (38). Mean atrial voltages were lower 
throughout the atria during coronary sinus pacing with 
300 msec as compared to 600 msec (1.56 ± 0.47 mV 
vs. 1.74 ± 0.48 mV, P<0.001). Furthermore, left supe-
rior pulmonary vein pacing at 300 msec resulted in 
even lower mean LA voltage as compared to coronary 
sinus pacing at the same cycle length and introduced 
more expressed voltage heterogeneity in the LA. In 
contrast to that in a cohort of 27 AF patients, Yagishita 
et al. reported a good correlation of electrogram am-
plitudes during AF and sinus rhythm. They also dem-
onstrated lower mean LA bipolar voltage measured at 
identical or adjacent locations in persistent compared 
to paroxysmal AF measured both in AF (0.81 ± 0.60 
mV vs. 0.58±0.62 mV, P<0.001) and in sinus rhythm 
(2.24 ± 1.51 mV vs. 1.56 ± 1.53 mV, P<0.001) (39). 
These findings support the notion that persistent AF is 
associated with more expressed atrial substrate which 
is not corroborated by other data as outlined above in 
the section on importance of AF phenotype. Another 
very recent study looks into the correlation of LA volt-
age during sinus rhythm and AF with zones of atrial 
fibrosis assessed by DE-MRI in 20 patients with per-
sistent AF (40). Atrial voltage assessed from multiple 
cycles during 8 second AF recordings was compared 
pairwise with the voltage at the same zones during si-
nus rhythm and correlated with the distribution of zones 
of delayed enhancement. The authors found a strong 
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correlation between LA voltages during sinus rhythm 
and those recorded during AF. When correlated with 
the distribution of fibrotic areas values recorded during 
AF demonstrated better diagnostic accuracy to predict 
fibrosis. A voltage cut-off of 0.35 mV in AF was found to 
detect fibrosis with a sensitivity and specificity of 75% 
and 79%, respectively. In contrast, a threshold of 
1.8 mV during sinus rhythm was able to identify zones 
of delayed enhancement with a sensitivity of 63% and 
sensitivity of 67%. A possible explanation for these 
results might be that low voltage during sinus rhythm 
identifies only zones where more coordinated wave 
fronts of activation encounter areas of conduction block 
and electrically inactivity typical for zones of compact 
fibrosis. The latter is only a part of the arrhythmogenic 
substrate identified by DE-MRI. During AF rapid and 
uncoordinated wave fronts spreading in areas of non-
compact fibrosis which are susceptible to slow conduc-
tion may be associated with the occurrence of low volt-
age. Validation of a voltage cut-off with mapping during 
AF has also been attempted by a recent study includ-
ing 31 AF patients where electrogram amplitudes of 
0.31 mV recorded during AF predicted minimal sinus 
rhythm electrogram amplitude of 0.5 mV with a sensitiv-
ity of 0.82 and a specificity of 0.95 (41).
These numerous caveats and limitations are a power-
ful call for new studies to elucidate the voltage cut-offs 
used in LA voltage mapping and standardise the meth-
odology by which LA voltage mapping is carried out. 
Further unknowns are introduced by many other fac-
tors which might have an impact on the results during 
LA voltage mapping. Among those electrode size and 
spacing, mapping density and tissue contact do play a 
considerable role.
Studies of tailored ablation approach  
based on atrial voltage
The approach to AF ablation targeting low voltage ar-
eas has been developing rapidly over the last 5 years. 
Among the first papers published on this topic is the 
one by Rolf et al. which provides interesting data from a 
non-randomised study (32). This study involved 178 AF 
patients all of which underwent detailed bipolar voltage 
map of the LA. All patients with low voltage (<0.5 mV) 
underwent additional substrate modification in addition 
to PVI. It included regional ablation at the low voltage 
zones (LVZ) aiming at substrate homogenisation meant 
to achieve defractionation, significant reduction of local 
electrograms and loss of capture while pacing with high 
energy output. In many cases linear lesions traversing 
through the diseased areas and connecting nonconduct-
ing zones were also performed. Larger LVZs were encir-
cled and electrically isolated. The study also included a 
control group of 26 patients with low voltage areas who 
underwent PVI only. In the study population LVZs were 
most frequently detected at the LA roof, anterior, poste-
rior wall and septum and were more common in persis-
tent cases. Ablation outcomes in patients with tailored 
substrate modification following PVI were comparable 
to those without LVZs undergoing PVI only. The control 
group had a poor outcome of a PVI strategy only. Results 
from this study generated hypotheses which were fur-
ther addressed by numerous subsequent studies 7DEOH
 (33, 34, 42–46). Most of these were observational and 
examined the outcomes of standard ablation in compari-
son to voltage guided ablation strategies in consecutive 
patients regardless of the presence of LVZs or compared 
outcomes of standard ablation versus standard ablation 
plus additional voltage-guided substrate modification in 
patients with LVZs.
Generally, a couple of ablation strategies have been 
used in all these studies )LJXUH Two of the papers 
coming from the same group report the so-called box 
isolation of fibrotic areas (BIFA). With this technique the 
areas in both atria affected by fibrosis as detected by 
electrogram amplitudes <0.5 mV were encircled by cir-
cumferential lesions. They were usually connected to 
pulmonary venous isolation or other lesion sets to pre-
vent occurrence of iatrogenic macroreentry circuits. The 
endpoint of BIFA was bidirectional block to and from the 
fibrotic area. This approach was tested in a small obser-
vational study of 41 AF patients (33). Ten of them were 
paroxysmal AF patients undergoing redo procedures for 
arrhythmia recurrence despite durable PVI where BIFA 
was reported to result in arrhythmia freedom in 90% of 
the cases. The rest of the patients were ablation-naïve 
NPAF patients. Thirteen of them (42%) underwent PVI 
only as they did not demonstrate LVZs in the LA (FACM 
0 and 1). The remaining 18 patients demonstrated 
fibro tic areas (FACM 2 to 4) and underwent additional 
BIFA. After a follow-up of 12.5 ± 2.4 months multiple 
procedure efficacy in this patient population was 83.3%. 
BIFA was indicated but impossible to perform due to 
very diffuse fibrosis in only one patient. These results 
give two very important messages. First, in about 40% 
of the NPAF patients in whom no LVZs are identified 
a strategy including PVI only appears to be effective. 
Second, there are patients with diffuse and dense fibro-
sis (FACM 4) in whom extensive ablation approaches of 
any kind should be discouraged because of low chance 
for long-term success. The same group extended their 
work to a larger series of patients. Schreiber et al. ana-
lysed the impact of LA fibrosis as assessed by electro-
gram voltage with regards to its distribution and rhythm 
outcome (42). This study included 49 patients without 
low voltage areas (FACM 0) who underwent PVI only 
and served as controls to 92 patients with FACM 1 to 4 
who underwent additional BIFA. Overall long-term suc-
cess rate from the study group was 84% after a single 
procedure and 94% following multiple procedures. The 
success rate was clearly dependent on FACM grade 
with FACM 3 and 4 patients demonstrating a consider-
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ably lower success rates as compared to FACM 1 and 
2. Not surprisingly, the lower success rate in the former 
group was driven by the FACM 4 patients who demon-
strated a success rate of only 20%.
Yagishita et al. analysed 201 AF patients (persistent in 
82%) who underwent electroanatomical mapping of the 
LA during AF (43). With a voltage cut-off of < 0.5 mV 
LVZs were identified in 79% of the patients who under-
went additional substrate modification – homogenisa-
tion and cavotricuspid isthmus ablation as appropriate. 
At 12 months and following a single procedure the ar-
rhythmia free rate for the whole study population was 
72%. After a long follow-up of 3.1 years success rate 
for the whole cohort after multiple procedures was 74%. 
There was no difference in the success rate between 
patients without LVZs undergoing PVI only and those 
with LVZs who underwent PVI and substrate modifica-
tion. One of the major and debatable findings this study 
is the high prevalence of LVZs (79%) which might be a 
result of mapping during AF. Jadidi et al. attempted to 
combine low-voltage and activation criteria during AF 
(44). They studied 85 NPAF patients who underwent 
voltage mapping during AF and subsequent PVI. When 
low voltage zones (<0.5 mV) were identified in the LA 
or right atrium, additional focal ablation was applied to 
those sites where electrical activity lasting more than 
70% of AF cycle length on single or multiple electrodes 
from a confined area. This strategy was applied to 62 
patients from the study cohort, 73% of whom had AF 
termination to sinus rhythm or atrial tachycardia. Fol-
lowing a median of 13 months of follow up 69% of the 
patients treated with PVI and additional selective atrial 
ablation were free from arrhythmia compared to only 
47% in the patients with PVI-only approach (P <0.001). 
Interestingly, the sites where AF terminated were found 
in LVZs in 80% of the cases and 20% were located at 
border zones.
Important findings have been reported by Yang et al. 
who studied 164 patients with NPAF (34). Eighty-six of 
those were treated with PVI and cavotricuspid isthmus 
ablation and subsequent substrate modification strate-
gy including ablation of all electrograms in LVZ (0.1-0.4 
mV) aiming to achieve substrate homogenisation. In ad-
dition, abnormal electrograms consisting of multiphasic 
electrograms with >3 distinct peaks and >50 msec dura-
tion in the so-called transitional zone (0.4-1.3 mV) were 
also targeted and eliminated. Short linear lesions were 
also placed to achieve dechanelling. A control group of 
patients underwent a stepwise ablation approach con-
sisting of PVI, followed in a stepwise manner by linear 
lesions and complex-fractionated electrogram ablation 
until AF termination. Long term success rates were sig-
nificantly higher in the study group: 70% vs. 51%, res-
pectively, P=0.011. Another important result reported 
by these investigators was the significantly higher rate 
of postprocedural atrial tachycardia in the control group 
(30% vs. 3.5% in the study group, P=0.0003). Similar 
findings were reported by <DPDJXFKLHWDO in a series 
of patients with NPAF undergoing PVI and homogeni-
sation of LVZs (45). Thirty-nine of the studied patients 
had LA LVZs (<0.5 mV). They underwent PVI and sub-
sequent substrate modification. The remaining 62 pa-
tients had no LVZs and underwent PVI only. In the two 
groups single procedure long-term success rates were 
Figure 1. Ablation strategies for individualised ablation based on LA voltage proposed by different groups. Panel A: Box iso-
lation of fibrotic areas as described by Kottkamp et al. and Schreiber et al. (34, 43). Panel B: Homogenisation of low voltage 
areas as proposed by Yagishita et al. and Yamaguchi et al. (44, 46). Panel C: Combined approach using linear ablation transec-
ting diseased areas (left panel), regional ablation targeting homogenisation of small low voltage areas (middle panel) and en-
circlement of larger low voltage areas by linear lesions connected to other non-conducting barriers e.g. PVI lesion sets or mitral 
annulus (right panel) as proposed by Rolf et al. and Kircher et al. (33, 47) Panel D Combined approach using identification 
of low voltage zones and focal ablation to sites of abnormal electrical activity as suggested by Jadidi et al. (45), see text for 
details. Panel E. Combined approach targeting homogenisation of low-voltage zones (0.1-0.4 mV) and elimination of abnormal 
electrograms in the transitional zone (0.4-1.3 mV) as used by Yang et al. (35, 48), see text for further details
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similar – 72% and 79% respectively. In contrast, in an 
additional group of patients with LVZs who underwent 
PVI only the long-term success rate was only 38%.
Direct comparison among these studies is difficult to 
make as they report quite heterogenous data in terms 
of mapping/ablation strategies, prevalence of LVZs, pa-
tient profile etc. In attempt to overcome these limitations 
Blandino et al. have combined data from six studies in 
a meta-analysis. Altogether 885 patients were enrolled 
of whom 92% had NPAF. Results from the combined 
strategy of PVI and voltage-guided ablation were supe-
rior when compared to the standard approach (PVI or 
PVI + empirical substrate ablation) in terms of long-term 
arrhythmia freedom – 70% vs. 43% respectively (OR = 
3.41, 95% CI 2.22–5.24) without a significant impact on 
adverse events rate. This strategy was also associated 
with lower occurrence of postablation atrial tachycar-
dias, shorter procedure duration and fluoroscopy times.
Two randomised studies with the voltage-guided abla-
tion strategy have also been performed with inconsist-
ent and contrasting results. Kircher et al. randomised 
124 AF patients to PVI or PVI and additional linear abla-
tion (for persistent cases only) or to PVI combined with 
ablation of LVZs (<0.5 mV in sinus rhythm) (47). The 
ablation strategy that was used was identical to the one 
proposed by Rolf et al. (32). Following a mean follow-up 
of 12 ± 3 months significantly more patients in the volt-
age guided ablation group met the primary endpoint of 
freedom from atrial arrhythmias off antiarrhythmic drugs 
after a single procedure (68% vs. 42%, P=0.003). Sec-
ondary efficacy endpoints (single procedure arrhyth-
mia free survival on or off antiarrhythmic drugs and sin-
gle procedure freedom from arrhythmias during 7-day 
Holter recording at 6 and 12 months) were also more 
common in the intervention group. Safety outcomes 
were comparable in the two groups. Contrary to that, 
Yang et al. reported similar long-term outcomes follow-
ing a single procedure in the randomised STABLE SR 
trial which enrolled 229 symptomatic NPAF patients 
(48). They were randomised to PVI combined with tai-
lored substrate modification versus stepwise approach. 
The former included homogenisation of low voltage 
zones (0.1-0.4 mV identified during sinus rhythm), elim-
ination of complex electrograms from the transitional 
zones (0.4-1.3 mV during sinus rhythm) and dechanel-
ling (34). The latter included PVI, followed in a stepwise 
fashion by linear ablation at the LA roof, the mitral isth-
mus and cavotricusid isthmus and subsequent ablation 
of complex fractionated electrograms in AF aiming at 
AF termination. In the intention-to-treat analysis the pri-
mary endpoint of freedom from AF or other atrial tach-
yarrhythmias at 18 months following a single procedure 
was not significantly different between the two groups 
(74% for the tailored intervention group vs 71.5% for the 
stepwise approach, P=0.3246). However, the tailored 
ablation approach was associated with significantly 
shorter procedure and fluoroscopic times as well as 
reduced energy delivery time. A potential explanation 
for the lack of consistency between these two studies 
might be slight differences in the patient characteristics: 
the patients from the STABLE SR cohort were main-
ly persistent cases but likely with less diseased atria 
(low average age, non-dilated atria and low CHADS2 
in the majority of the subjects). On the other hand, in 
the study by Kircher et al. the freedom from arrhythmia 
recurrence in the paroxysmal patients from the control 
group was lower than expected and previously reported 
which might have affected the results and strengthen 
the difference between the two groups.
Conclusion
Atrial fibrosis plays an important role in the complex 
pathophysiology of both paroxysmal and non-paroxys-
mal AF. Location and extent of fibrotic areas are highly 
variable and ablation strategies implementing empirical 
linear lesions or fragmented electrogram ablation might 
leave great parts of these areas untreated thus decreas-
ing long-term ablation success. This holds true espe-
cially for the NPAF patients in which arrhythmogenic 
atrial substrate plays a greater role. On the other hand, 
some patients with less expressed substrate are over-
treated with the potential risk of increased complication 
rates. Therefore, ablation strategies tailored to the sub-
strate in each individual patient would provide one of the 
most effective rhythm control options in paroxysmal and 
non-paroxysmal AF. Voltage mapping is a rapid proce-
dure providing intuitive data on the distribution of fibrotic 
areas in the atria by demonstration of LVZs. However, 
this technique is not devoid of limitations and some ar-
eas such as exact voltage cut-off values that could be 
utilised to identify fibrotic areas most accurately require 
further study. Despite this many observational studies 
demonstrate clear benefit from a voltage guided ablation 
approach. Randomised data are as yet inconclusive in 
terms of success but appears to show better procedur-
al characteristics compared to the empirical approach. 
Further evidence from large prospective multicentre ran-
domised trials is needed to establish the safety profile 
of such an approach and to further verify its efficacy as 
compared to standard ablation.
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